RxDoctor Payments Data

Mary Donna Cruz, MD

Advanced Heart Failure and Transplant Cardiology · Bethlehem, PANPI 1922305952

Payments from drug & device makers

$2,387in general payments, 2019–2025

Across 65 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$410
  • Edwards Lifesciences$328
  • Impulse Dynamics (USA) Inc.$294
  • Novartis$217
  • AstraZeneca$178
  • Pfizer$140
  • plus $819 from 15 others

What the payments were for

  • Food & beverage$2,37399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,387 in reported general payments places this provider in the 20th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$120,640
Medicare patients
388
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis44$1,142,744
OpsumitMacitentan68$815,615
UptraviSelexipag14$334,887
EntrestoSacubitril/Valsartan350$334,425
AdempasRiociguat24$304,774
WinrevairSotatercept-Csrk11$270,080
JardianceEmpagliflozin415$266,515
EliquisApixaban206$226,362
Orenitram ErTreprostinil Diolamine44$198,740
Tadalafil61$146,367
Ambrisentan21$97,569
FarxigaDapagliflozin Propanediol49$60,824
XareltoRivaroxaban35$47,811
AdcircaTadalafil11$39,482
CorlanorIvabradine Hcl13$12,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$140$1,369,106250 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$140$1,150,50282 claims
NovartisEntresto$217$334,425350 claims
Boehringer IngelheimJardiance$27$266,515415 claims
AstraZenecaFarxiga$178$60,82449 claims
Johnson & JohnsonXarelto$26$47,81135 claims
United Therapeutics CorporationAdcirca$125$39,48211 claims
AmgenCorlanor$36$12,65013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →